ShanX Medtech Secures €24 Million to Fast Track Ultra Rapid Diagnostics Against Antimicrobial Resistance

The ShanX Medtech team. Photo: ShanX Medtech

(IN BRIEF) ShanX Medtech, a spin-off from Eindhoven University of Technology, has raised €24 million in combined public and private funding to accelerate the development of its ultra-rapid antimicrobial susceptibility testing platform. The financing includes an oversubscribed €15 million seed round and an €8.85 million European Commission-backed contract, supporting clinical validation, regulatory approval, and market entry. By delivering antibiotic susceptibility results within one hour directly from patient samples, the technology aims to address the growing threat of antimicrobial resistance and enable faster, evidence-based treatment decisions. The milestone highlights both strong investor confidence in ShanX Medtech’s approach and the broader impact of TU/e research on global healthcare innovation.

(PRESS RELEASE) EINDHOVEN, 9-Jan-2026 — /EuropaWire/ — ShanX Medtech, a spin-off from Eindhoven University of Technology, has secured a combined €24 million in funding to accelerate the development and rollout of its ultra-rapid antimicrobial susceptibility testing technology. The investment represents a major step forward for the Eindhoven-based MedTech company and highlights the growing real-world impact of TU/e-driven research on critical global healthcare challenges.

Photo: ShanX Medtech

The financing package includes an oversubscribed €15 million seed round alongside an €8.85 million contract awarded by the European Commission through the Health Emergency Preparedness and Response Authority in collaboration with the European Health and Digital Executive Agency. Together, the funds will enable ShanX Medtech to complete final product development, conduct clinical validation studies, obtain regulatory approvals, and prepare for market entry of its in-vitro diagnostic platform.

Antimicrobial resistance remains one of the most pressing threats to modern medicine, placing increasing strain on healthcare systems worldwide. In many clinical settings, physicians must prescribe antibiotics without knowing whether a pathogen will respond, as existing diagnostic tools often require days and access to specialised laboratories. These delays can lead to ineffective treatments, unnecessary antibiotic use, and the accelerated spread of resistant bacteria.

ShanX Medtech is addressing this challenge with a diagnostic platform capable of delivering comprehensive antimicrobial susceptibility results within one hour. The technology works directly from patient samples and requires minimal hands-on time, making it suitable for both central laboratories and point-of-care environments. By applying novel chemistry to track microbial metabolism, the platform supports faster, evidence-based treatment decisions that could significantly improve patient outcomes while helping curb antimicrobial resistance.

Founded in 2019, ShanX Medtech grew directly out of research and entrepreneurial initiatives at TU/e and is now headquartered at the High Tech Campus Eindhoven. Founder and Chief Executive Officer Sophia E. Shanko and Chief Scientific Officer Ardjan van der Linden both completed their doctoral research at TU/e, where they developed the scientific foundation of the company and first connected as collaborators. Shanko carried out her PhD under the supervision of Professor Jaap den Toonder from TU/e’s Department of Mechanical Engineering, an experience she credits as instrumental in shaping both the technology and her entrepreneurial direction.

The origins of the company are rooted in a concrete clinical experience. Shanko explains that a single patient case, in which delayed diagnostic results had serious consequences, underscored the urgent need for faster and more reliable testing solutions. The latest funding round, she notes, brings the company significantly closer to making ultra-rapid antimicrobial susceptibility testing available across a wide range of clinical settings.

The equity portion of the seed round was led by Borski Fund, with participation from NextGen Ventures, CbusineZ, the Brabant Development Agency, Invest-NL, and a strategic angel fund. Investors cite the global urgency of antimicrobial resistance and the broad scalability of ShanX Medtech’s platform across multiple clinical applications as key drivers behind their support.

With the new capital in place, ShanX Medtech plans to expand its team, deepen clinical collaborations, and lay the groundwork for commercial launch. The company’s continued progress reinforces Eindhoven’s role as a leading European centre for MedTech innovation and demonstrates how TU/e spin-offs are translating academic research into solutions with global healthcare impact.

Media Contact:

Tel: +31 (0)40 247 9111

SOURCE: TU/e